Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepantronium bromide plus rituximab in relapsed/refractory c-Myc-driven Burkitt lymphoma and other high-grade B-cell lymphomas (Phase II, China)
CTR20252316Phase 2Active
- Sponsor
- Createrna Science & Technology
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sepantronium in Burkitt lymphoma (BL), large-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), sponsored by Createrna Science & Technology. Started Jun 2025; status: active.
02
Drugs
sepantronium
03
Conditions
Burkitt lymphoma (BL)large-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20252316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252316.